Utilidad clínica del biomarcador sérico propéptido N-terminal del procolágeno tipo 1 (P1NP) en mujeres diabéticas tipo 2 postmenopáusicas

Alterations in bone remodeling and Type 2 Diabetes Mellitus (DM2) are relevant health-related issues in postmenopause, which are associated with bone fragility and factors affecting the glucose metabolism and bone metabolism. Osteoporosis diagnostic criteria are defined by measurement of bone mineral density, which, in DM2, is limited. The amino-terminal propeptide of procollagen type I (P1NP) has been proposed as an excellent noninvasive biomarker of bone formation. The aim of the present study was to evaluate the clinical usefulness of P1NP levels in dynamic processes of bone formation in type 2 diabetic postmenopausal women. A cross-sectional study has been conducted. Determinations performed were: Dual Radiological Densitometry, Creatinine, Total and Ionic Calcium, phosphorus, vitamin D, parathormone, glycated hemoglobin and P1NP. Two groups of postmenopausal women were defined: control non-Diabetic women and DM2 diagnosed women. One hundred and four non-diabetic and DM2 diagnosed women were evaluated and, divided according to the T-Score by densitometry: with and without alterations in bone remodeling. P1NP concentrations were higher in the groups with alterations than in those without alterations in bone remodeling (p <0.001). P1NP levels in the control group were higher than those of diabetic women. (62.8 ± 25.8 vs 31.4 ± 7.8) ng/ml, p < 0.0001. P1NP measurement could be useful to detect variations in the bone turnover. This information with densitometry by Dual Radiologic Densitometry increases the performance of the evaluation of the states of bone disease in postmenopausal postmenopausal women in DM2.